Breaking Barriers: Sandhoff Disease Pipeline Advances and Hopeful Therapies

DelveInsight’s 2025 report on the Sandhoff Disease Pipeline offers extensive insights into over 5 companies and more than 5 drugs in development. It includes profiles of pipeline therapies at clinical and non-clinical stages, evaluations by product type, development phase, administration method, and molecular category. The report also covers inactive projects in this therapeutic area.

Explore the newest medications and treatment approaches in the Sandhoff Disease Pipeline. Access DelveInsight’s thorough report now at Sandhoff Disease Pipeline Outlook

Key Highlights from the Sandhoff Disease Pipeline Report

• DelveInsight’s Sandhoff Disease Pipeline analysis highlights a dynamic field with over 5 active organizations creating more than 5 therapies for Sandhoff Disease management.

• Leading companies in Sandhoff Disease include IntraBio, Sanofi, Polaryx Therapeutics, Azafaros, and others.

• Promising therapies encompass IB1001, Zavesca (Miglustat), TSHA-101, Miglustat, and more.

Keep up with the latest pipeline developments for Sandhoff Disease. Gain knowledge on clinical trials, emerging treatments, and top companies through DelveInsight at Sandhoff Disease Treatment Drugs

Profiles of Emerging Sandhoff Disease Drugs

• IB1001: IntraBio
  IB1001, or N-acetyl-L-leucine, is an oral modified amino acid. Research shows it to be the effective isomer of N-acetyl-DL-leucine, capable of restoring brain function and slowing disease progression in various neurological pathways. Its multi-faceted action includes changes in glucose and antioxidant processes, decreased lysosomal buildup, and reduced inflammation in the cerebellum, which helps prevent cell death. IntraBio is running a multinational, multicenter, open-label, rater-blinded Phase II study to evaluate IB1001's safety and effectiveness for GM2 Gangliosidosis (including Tay-Sachs and Sandhoff Disease).

• Venglustat: Sanofi
  Venglustat is an investigational oral treatment designed to halt the advancement of certain conditions by blocking excessive glycosphingolipid (GSL) buildup. GSLs are essential cell components, and their abnormal accumulation contributes to cell issues and disease worsening in rare disorders. The drug is currently in Phase III trials for Sandhoff Disease.

Sandhoff Disease Pipeline Report Insights

• The report delivers detailed information on companies developing Sandhoff Disease therapies, including the number of treatments each is pursuing.

• It categorizes therapeutic options into early, mid, and late development stages for Sandhoff Disease care.

• Companies focus on targeted drug creation, with details on active and inactive (dormant or terminated) projects.

• Drugs in development are analyzed by stage, administration route, target receptor, monotherapy or combination, mechanism of action, and molecular type.

• Comprehensive review of partnerships (company-to-company and company-academia), licensing deals, and funding to support Sandhoff Disease market progress.

Discover innovative treatments and trials in the Sandhoff Disease Marketed and Pipeline Drugs. Get DelveInsight’s full report today at New Sandhoff Disease Drugs

Sandhoff Disease Companies

Key players include IntraBio, Sanofi, Polaryx Therapeutics, Azafaros, and others.

Sandhoff Disease Therapeutic Assessment by Route of Administration

The report classifies pipeline drugs by delivery methods, such as:

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Sandhoff Disease Products by Molecule Type

Products are grouped by molecular categories, including:

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Reveal the future of Sandhoff Disease Treatment. Learn about novel drugs, pipeline progress, and major companies with DelveInsight’s expert analysis at Sandhoff Disease Market Drivers and Barriers

Scope of the Sandhoff Disease Pipeline Report

• Coverage: Global

• Sandhoff Disease Companies: IntraBio, Sanofi, Polaryx Therapeutics, Azafaros, and others.

• Sandhoff Disease Therapies: IB1001, Zavesca (Miglustat), TSHA-101, Miglustat, and others.

• Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, or Both.

• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Obtain the most current information on Sandhoff Disease Therapies and clinical trials. Download DelveInsight’s detailed pipeline report now at Sandhoff Disease Companies, Key Products and Unmet Needs

About DelveInsight

DelveInsight is a top-tier market research and consulting firm focused on healthcare, delivering high-quality intelligence and analysis to guide strategic decisions. Our team of industry experts, with deep expertise in life sciences and healthcare, provides tailored solutions and global insights. Reach out for reliable, current data to stay ahead in the industry.

Contact Us 

Kanishk

kkumar@delveinsight.com